Literature DB >> 3263099

Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis.

H L Israel1.   

Abstract

Cyclophosphamide has proved to be the most effective therapy for Wegener's granulomatosis, but mortality remains high at many medical centers, and the necessity for giving this toxic agent for many years to prevent relapses remains a major problem. Successful treatment of this disease with sulfamethoxazole-trimethoprim has been reported by DeRemee et al, and experience in a series of ten patients at Thomas Jefferson University Hospital, Philadelphia, confirms its effectiveness. Nine patients are in remission, and the condition of one patient improved. Relapses occurred in four patients after intervals of remission ranging from four to 30 months, but responded to increased doses of trimethoprim in two patients, while two patients required resumption of therapy with cytotoxic agents. Although the effects of sulfamethoxazole-trimethoprim are suppressive rather than curative, its use represents a major advance in treatment of Wegener's granulomatosis, permitting successful treatment of many patients without high toxic doses of cyclophosphamide and prednisone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263099

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

Review 1.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 2.  An unusual case of multiple cranial nerve palsies in Wegener's granulomatosis.

Authors:  A D Daderian; S Chayasirisobhon
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

Review 3.  The current status of neutrophil cytoplasmic antibodies.

Authors:  F J van der Woude; M R Daha; L A van Es
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 4.  [Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement].

Authors:  M Laudien; P Ambrosch; A Till; R Podschun; P Lamprecht
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 5.  Pulmonary vasculitis.

Authors:  A Burns
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 6.  Wegener's granulomatosis. Thoughts and observations of a pathologist.

Authors:  F Wegener
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 7.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

8.  Wegener granulomatosis causing sellar mass, hydrocephalus, and global pituitary failure.

Authors:  R D Bertken; V R Cooper
Journal:  West J Med       Date:  1997-07

Review 9.  Diagnostic approach to patients with suspected vasculitis.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

Review 10.  Chronic suppurative lung disease with associated vasculitis.

Authors:  I N Bruce; J A McAteer; P V Gardiner; R J McFarland; J M Sloan; A L Bell
Journal:  Postgrad Med J       Date:  1995-01       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.